Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03829501 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

Start date: January 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.

NCT ID: NCT03794440 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Start date: February 11, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label,Multi-center Study. The primary endpoint is overall survival.

NCT ID: NCT03782207 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

IMreal
Start date: February 7, 2019
Phase:
Study type: Observational

This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.

NCT ID: NCT03781934 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.

NCT ID: NCT03778957 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

EMERALD-1
Start date: November 30, 2018
Phase: Phase 3
Study type: Interventional

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

NCT ID: NCT03755791 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

COSMIC-312
Start date: June 10, 2018
Phase: Phase 3
Study type: Interventional

This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

NCT ID: NCT03752398 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

DUET-3
Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

NCT ID: NCT03744624 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Application of 3D Printing in Laparoscopic Surgery of Liver Tumors

Start date: April 28, 2017
Phase: N/A
Study type: Interventional

To explore the utility of personalized 3D printed liver models in planning and navigating laparoscopic resections.

NCT ID: NCT03742453 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis

Start date: October 16, 2018
Phase: N/A
Study type: Interventional

This study aims to compare the diagnostic accuracy of Contrast-enhanced ultrasound (CEUS) for diagnosing hepatocellular carcinoma (HCC) with that of gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) using non-invasive diagnostic criteria (American Association for the Study of Liver Disease (AASLD or Liver Imaging Reporting and Data System (LI-RADS) v2018 and Korean Liver Cancer Study Group- National Cancer Center Korea (KLCSG-NCC) v2018).

NCT ID: NCT03731923 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Abbreviated MRI for HCC Surveillance

Start date: November 8, 2018
Phase: N/A
Study type: Interventional

This study aims to investigate the clinical feasibility of abbreviated liver MRI for HCC surveillance in a high-risk group.